# US 11,998,571 B2 · Pharmaceutical composition comprising stem cell-conditioned medium and exosome isolated therefrom as active ingredient for prevention or treatment of ocular disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,998,571 B2
- Document ID: US11998571B2
- Status: Granted
- Kind: B2
- Application number: 18/046,719
- Filed: 2022-10-14
- Published: 2023-05-04
- Granted: 2024-06-04
- Earliest claimed: 2021-11-02
- Assignees: Designed Cells Co.,Ltd.
- Applicants: Designed Cells Co., Ltd.
- Inventors: Yun Bae Kim; Ehn Kyoung Choi; Tae Myoung Kim
- Web page: https://patentgrep.com/patent/US11998571B2

## CPC

- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 35/50: Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
- A23L 33/10: using additives (addition of substantially indigestible substances A23L33/21)
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- C12N 5/0605: {Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly}
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- C12N 5/0668: {Mesenchymal stem cells from other natural sources}
- C12N 2500/02: Atmosphere, e.g. low oxygen conditions
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

Disclosed herein is a pharmaceutical composition comprising at least one selected from the group consisting of a stem cell-conditioned medium and an exosome isolated therefrom as an active ingredient for prevention or treatment of an ocular disease. Containing exosomes, growth factors and neurotrophic factors at high levels and functioning to: promote retinal cell proliferation and wound recovery; protect retinal cells against oxidative stress or hypoxia; lower the increased intraocular pressure and restore the atrophy of the retinal layer and the retinal ganglion cell layer to normal levels in the glaucoma animal model; and have a protective effect on retinal ganglion cells and nerve cells, the stem cell-conditioned medium according to the present disclosure can find advantageous applications in the therapy of an ocular disease.

## Claims

### Claim 1

A method for alleviating or treating glaucoma, the method including a step of administering to a subject suffering from glaucoma at least one selected from the group consisting of a stem cell-conditioned medium and an exosome isolated therefrom, wherein the stem cells are amnion-derived stem cells, and wherein the amnion-derived stem cells are selected one or more from the group consisting of amniotic membrane-derived mesenchymal stem cells and amniotic membrane-derived epithelial stem cells.

### Claim 2 (depends on 1)

The method of claim 1, wherein the stem cell-conditioned medium is obtained by culturing stem cells at an oxygen concentration of 10% or less.

### Claim 3 (depends on 2)

The method of claim 2, wherein the stem cell-conditioned medium is obtained by culturing stem cells at an oxygen concentration of 1 to 5%.

### Claim 4 (depends on 1)

The method of claim 1, wherein administration of the at least one selected from the group consisting of a stem cell-conditioned medium and an exosome isolated therefrom to the subject decreases intraocular pressure.